This trial will test a new drug to help people with swelling in the middle of their eye caused by inflammation.
- Uveitic Macular Edema
1 Primary · 21 Secondary · Reporting Duration: Weeks 20 and 52
3 Treatment Groups
1 of 3
1 of 3
1 of 3
225 Total Participants · 3 Treatment Groups
Primary Treatment: Arm A · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How secure is Arm A for participants?
"Our internal assessment at Power ranked Arm A's safety as a 3 due to the Phase 3 trial data that shows efficacy and multiple rounds of evidence-based security." - Anonymous Online Contributor
Are patient enrollments still open for this particular research study?
"Yes, per the resources on clinicaltrials.gov this study is actively enrolling patients. It was first announced in March 10th 2023 and has been updated as recently as 3/3/2023. 225 participants are needed from 2 medical centres to complete the trial." - Anonymous Online Contributor
How many participants are being recruited for this trial?
"Affirmative. Clinicaltrials.gov reveals that this investigation is currently looking for qualified individuals, with the initial posting taking place on March 10th 2023 and a subsequent update occurring 3/3/2023. A total of 225 candidates are required at two distinct medical facilities." - Anonymous Online Contributor